Jack Waxman, MD
Rheumatology · Santa Rosa, CANPI 1104824994
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $46,798 of the $75,335 with a category attached, or 62.1%. 32 manufacturers reported payments, led by Amgen at 45.9% of the total. Reporting peaked in 2019 at $50,774 and has fallen 97.9% since, to $1,058 in 2025. Among rheumatology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 930 payments — averaging $81.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$35K
- Novartis$24K
- Pfizer$5K
- AbbVie$3K
- Radius Health, Inc.$1K
- GSK$832
- plus $6K from 26 others
What the payments were for
- Consulting fees$1250%
- Speaking & faculty fees$46,79862%
- Travel & lodging$7,25710%
- Food & beverage$20,77128%
- Education$3841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 309 | $34,583 |
| Novartis | 83 | $24,099 |
| Pfizer | 69 | $5,159 |
| AbbVie(2 entities) | 109 | $3,309 |
| Radius Health, Inc. | 72 | $1,356 |
| GSK | 40 | $832 |
| Janssen Scientific Affairs, LLC | 13 | $829 |
| Johnson & Johnson | 43 | $662 |
| E.r. Squibb & Sons, L.L.C. | 21 | $542 |
| UCB, Inc. | 17 | $526 |
| Mallinckrodt Hospital Products Inc. | 21 | $450 |
| Sanofi | 16 | $429 |
| AstraZeneca(2 entities) | 19 | $366 |
| Biohaven Pharmaceuticals, Inc. | 22 | $327 |
| Bristol Myers Squibb | 16 | $323 |
| Lilly USA, LLC | 13 | $275 |
| Boehringer Ingelheim | 8 | $273 |
| Mallinckrodt Enterprises LLC | 10 | $221 |
| Aurinia Pharma U.S., Inc. | 2 | $176 |
| Tersera Therapeutics LLC | 1 | $125 |
| Genentech USA, Inc. | 5 | $106 |
| Hikma Pharmaceuticals USA | 4 | $76 |
| Biogen | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $44 |
| Genentech, Inc. | 1 | $39 |
| Medexus Pharma, Inc. | 2 | $38 |
| Gilead | 1 | $34 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Assertio Therapeutics, Inc. | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,335 in reported general payments places this provider in the 90th percentile of 808 rheumatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Santa Rosa
- Sudhakar TumuluriSan Francisco$2.8M
- Ara DikranianSan Diego$2.2M
- Orrin TroumSanta Monica$1.8M
- Robin DoreTustin$1.5M
- Samy MetyasCovina$1.3M
- Rhonda LambertSan Mateo$1.1M
- William ShielMission Viejo$924K
- Mark BoriginiDowney$920K
- Adam KreitenbergTarzana$863K
- Roger KornuTustin$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.